LifeMine Therapeutics
Develops fungal genome-derived therapeutics for organ transplant rejection
$263MSeries D+Series E
Role not disclosedLoading investors…
Activity from announced rounds
Develops fungal genome-derived therapeutics for organ transplant rejection
Develops medicines targeting historically undruggable protein targets in cancer
Pitching Milky Way Investments? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room